secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K/A
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0001104659-26-010965
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools completes sale of SomaScan business to Illumina for ~$363.7M net cash
--------------------------------------------------------------------------------

- Net cash proceeds of ~$363.7M from sale of SomaLogic and Sengenics entities to Illumina.
- Potential earnout payments up to $75M based on 2025/2026 revenue milestones.
- Pro forma cash and equivalents of $478.3M as of Sep 30, 2025; gain on sale of $161.9M.
- Company retains mass cytometry and microfluidics businesses; no longer party to Collaboration Agreement.
- Transaction expenses of $18.4M incurred; $14.8M paid at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000110465926010965/0001104659-26-010965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000110465926010965/tm265294d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-010965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer